DBV Technologies SA - Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years - Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the DBV Technologies Regulatory Update Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand over the conference to your speaker for today, Sara Sherman, Investor Relations at DBV. You may begin.
Thank you, Dilem, and thank you all for joining today's call. Earlier today, we issued a press release providing a regulatory update for Viaskin Peanut, our lead product candidate for the treatment of peanut-allergic children 4 to 11 years of age. The press release is available on our website at dbv-technologies.com as well as on the SEC website.
Joining me on the call today are our CEO, Daniel Tassé; and our CMO, Pharis Mohideen. Daniel will deliver remarks, and then we'll open up the call for Q&A.
I would like to note that during our call today, we will make a number of statements that are forward-looking, including but not limited to the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
